Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04018950 Org: User:
Start: 06/21/19 End: 07/26/19 Due: 07/26/20

AZD0914 Phase 1 ADME Study in Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02298920 Org: User:
Start: 01/31/15 End: 02/28/15 Due: 02/28/16

Evaluation of the Safety, Tolerability and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02971423 Org: User:
Start: 10/31/16 End: 06/01/17 Due: 06/01/18

Study to Determine and Compare Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03303924 Org: User:
Start: 08/21/17 End: 10/26/17 Due: 10/26/18

Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections

Phase: N/A Priority: Normal
NCT ID: NCT03445195 Org: User:
Start: 01/17/18 End: 05/17/18 Due: 05/17/19

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT03491748 Org: User:
Start: 03/16/18 End: 09/11/19 Due: 09/11/20

Evaluation of the Pharmacokinetics, Safety, and Tolerability of Intravenous ETX2514 and Sulbactam Administered Concurrently to Subjects With Various Degrees of Renal Impairment and Healthy Matched Control Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03310463 Org: User:
Start: 10/03/17 End: 05/29/18 Due: 05/29/19

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03985410 Org: User:
Start: 05/23/19 End: 07/24/19 Due: 07/24/20

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex

Phase: N/A Priority: Normal
NCT ID: NCT03894046 Org: User:
Start: 09/05/19 End: 07/26/21 Due: 07/26/22